Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

@article{moukhine2026anticd20,
  title = {{Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis}},
  author = {Alexia Moukhine and Fabien Rollot and Romain Casey and Nicolas Collongues and Sandra Vukusic and Guillaume Mathey and Anne-Laure Dubessy and Jonathan Ciron and Jérôme de Sèze and Aurélie Ruet and Pierre Labauge and Arnaud Kwiatkowski and Hélène Zéphir and Caroline Papeix and Gilles Defer and Christine Lebrun-Frenay and David-Axel Laplaud and Eric Berger and Eric Thouvenot and Jean Pelletier and Abdullatif Al Khedr and Olivier Casez and Bertrand Bourre and Abir Wahab and Laurent Magy and Jean-Philippe Camdessanché and Inès Doghri and Solène Moulin and Mariana Sarov-Rivière and Karolina Hankiewicz and Amélie Dos Santos and Corinne Pottier and Éric Manchon and Jennifer Aboab and Maya Tchikviladze and Thomas David and Gilles Edan and Emmanuelle Le Page and Laure Michel and Anne Kerbrat},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  month = aug,
  doi = {10.1002/acn3.70497},
  url = {https://inserm.hal.science/inserm-05778909v1},
  note = {CC BY-NC-ND 4.0},
}

TY  - JOUR
TI  - Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis
AU  - Alexia Moukhine
AU  - Fabien Rollot
AU  - Romain Casey
AU  - Nicolas Collongues
AU  - Sandra Vukusic
AU  - Guillaume Mathey
AU  - Anne-Laure Dubessy
AU  - Jonathan Ciron
AU  - Jérôme de Sèze
AU  - Aurélie Ruet
AU  - Pierre Labauge
AU  - Arnaud Kwiatkowski
AU  - Hélène Zéphir
AU  - Caroline Papeix
AU  - Gilles Defer
AU  - Christine Lebrun-Frenay
AU  - David-Axel Laplaud
AU  - Eric Berger
AU  - Eric Thouvenot
AU  - Jean Pelletier
AU  - Abdullatif Al Khedr
AU  - Olivier Casez
AU  - Bertrand Bourre
AU  - Abir Wahab
AU  - Laurent Magy
AU  - Jean-Philippe Camdessanché
AU  - Inès Doghri
AU  - Solène Moulin
AU  - Mariana Sarov-Rivière
AU  - Karolina Hankiewicz
AU  - Amélie Dos Santos
AU  - Corinne Pottier
AU  - Éric Manchon
AU  - Jennifer Aboab
AU  - Maya Tchikviladze
AU  - Thomas David
AU  - Gilles Edan
AU  - Emmanuelle Le Page
AU  - Laure Michel
AU  - Anne Kerbrat
PY  - 2026
DA  - 2026/08/13
JO  - Annals of Clinical and Translational Neurology
DO  - 10.1002/acn3.70497
UR  - https://inserm.hal.science/inserm-05778909v1
AB  - Objective: To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy. Methods: This observational, multicenter, retrospective cohort study included 2283 patients from the French MS registry aged > 50, who had received at least two cycles of anti‐CD20 and had experienced no relapses or MRI activity for at least one year prior to inclusion. Patients were classified as discontinuing or continuing therapy and 1:1 matched using a time‐dependent propensity score. Outcomes were time to first relapse, inflammatory activity (relapse and/or MRI activity), confirmed disability accrual, and serious infection. Results: Among 1900 patients continuing therapy and 383 discontinuing, 224 in each group were matched (mean age = 57.7 ± 5.9 years; mean EDSS = 5.4 ± 1.7; median follow‐up after matching = 34.8 [21.6–50.4] months). There were no significant differences between groups in time to first relapse (HR = 0.6, 95% CI 0.3–1.3, p = 0.2), inflammatory activity (HR = 0.9, 95% CI 0.5–1.4, p = 0.6), confirmed disability accrual (HR = 1.2, 95% CI 0.9–1.7, p = 0.2), and serious infections (HR = 1.0, 95% CI 0.6–1.8, p = 0.9). Interpretation: This retrospective study found no evidence of differences between stopping and continuing anti‐CD20 therapy regarding relapse, inflammatory activity, disability accrual, or serious infections in older patients with long‐standing non‐active MS over a median 2.9‐year follow‐up.
SN  - 2328-9503
SN  - 2328-9503
ER  -